Clinical Case Reports (Aug 2021)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine

  • Agaath Hedina Manickam,
  • Alina Buture,
  • Esther Tomkins,
  • Martin Ruttledge

DOI
https://doi.org/10.1002/ccr3.4625
Journal volume & issue
Vol. 9, no. 8
pp. n/a – n/a

Abstract

Read online

Abstract Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies. These molecular treatments are a relatively new class of drugs for the prevention of migraine. It is likely that we will see this side effect more often in the future. Patients with a background of Raynaud's phenomenon may experience worsening of their symptoms if started on these treatments.

Keywords